KOD

Fosun International: Total Revenue for 2023 Reached RMB198.2 billion, Industrial Operation Profit Increased by 20% YoY

Retrieved on: 
Wednesday, March 27, 2024
Gene, Mining, PPT, Cell, RMB, Patient, Rehabilitation, TCFD, Marketing, World Health Organization, HSI, Artesunate, Carcinoma, MSCI, FTG, Telehealth, Lithium, National Medical Products Administration, HKEX, Sustainability, SCLC, AA, KOD, NMPA, Growth, Hope, Fosun Pharma, S&P, Task force, Club Med, Dragon

HONG KONG, March 27, 2024 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656, "Fosun International"), together with its subsidiaries ("Fosun" or the "Group"), today announced its annual results for the year ended 31 December 2023 (the "Reporting Period").

Key Points: 
  • During the Reporting Period, the Group achieved a total revenue of RMB198.2 billion, representing a year-on-year increase of 8.6%.
  • Thanks to the Group's global business presence and continuous innovation, industrial operation profit reached RMB4.9 billion, representing a year-on-year increase of 20%.
  • Total revenue of the four core subsidiaries, namely Yuyuan, Fosun Pharma, Fosun Insurance Portugal and Fosun Tourism Group (FTG), was RMB142.69 billion, representing  a year-on-year increase of 8%, contributing 72% of the revenue.
  • In 2023, Fosun's overseas revenue reached RMB89.2 billion, representing a year-on-year growth of 6% and accounting for 45% of the total revenue.

Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

Retrieved on: 
Tuesday, March 26, 2024
KOD, Webcast, Therapy, PALO

PALO ALTO, Calif., March 26, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that it will report fourth quarter and full-year 2023 financial results on Thursday, March 28, 2024.

Key Points: 
  • PALO ALTO, Calif., March 26, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that it will report fourth quarter and full-year 2023 financial results on Thursday, March 28, 2024.
  • Management will host a conference call and live webcast to discuss recent business highlights and provide a corporate update at 4:30 p.m. Eastern Time on March 28, 2024.
  • A live audio webcast of the event will be available on the "Events and Presentations" section of Kodiak's Investors & Media website at http://ir.kodiak.com/ .
  • A replay of the webcast will be available for a limited time following the event.

Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting

Retrieved on: 
Tuesday, January 30, 2024
Senior, Angiogenesis, Patient, PALO, ABC, Clinical research, University, Outline, Partner (business rank), Safety, Disease, Diabetic retinopathy, Therapy, Inflammation, KOD, Retina, Multiple, DME, Vaccine

PALO ALTO, Calif., Jan. 30, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that first time results of the KSI-501ABC Phase 1 Study will be presented at the Angiogenesis, Exudation, and Degeneration 2024 virtual meeting.

Key Points: 
  • PALO ALTO, Calif., Jan. 30, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that first time results of the KSI-501ABC Phase 1 Study will be presented at the Angiogenesis, Exudation, and Degeneration 2024 virtual meeting.
  • KSI-501ABC is the second product candidate built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform.
  • "We look forward to sharing for the first time the results of our Phase 1 study of KSI-501ABC, our anti-IL-6 antibody and VEGF-trap bispecific therapeutic candidate in its antibody biopolymer conjugate form.
  • We believe these early results support further clinical development of the KSI-501 program," said Dr. J. Pablo Velazquez-Martin, MD., Senior Vice President of Clinical Research and Development.

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 4, 2024
Conference, KOD, PALO, Therapy

PALO ALTO, Calif., Jan. 4, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024, at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

Key Points: 
  • PALO ALTO, Calif., Jan. 4, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024, at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).
  • A live webcast of the presentation will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the event.

Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society

Retrieved on: 
Wednesday, October 11, 2023
Incidence, RVO, DME, KOD, Therapy, Ranibizumab, Safety, AMD, GLEAM, Diabetic retinopathy, Cataract, GLIMMER, Patient, Year 1 (education), PALO, Pharmaceutical industry

PALO ALTO, Calif., Oct. 11, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that three scientific presentations on tarcocimab tedromer (KSI-301), including a first-time presentation of the primary results from the Phase 3 DAYLIGHT study in wet age-related macular degeneration (AMD), a first-time presentation of the Year 1 head-to-head results from the Phase 3 BEACON study in retinal vein occlusion (RVO), and the primary results and new analyses from the Phase 3 GLEAM and GLIMMER studies in diabetic macular edema (DME), will be shared at the 56th Annual Scientific Meeting of The Retina Society, being held from Oct 11 – 14 in New York, United States.

Key Points: 
  • PALO ALTO, Calif., Oct. 11, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that three scientific presentations on tarcocimab tedromer (KSI-301), including a first-time presentation of the primary results from the Phase 3 DAYLIGHT study in wet age-related macular degeneration (AMD), a first-time presentation of the Year 1 head-to-head results from the Phase 3 BEACON study in retinal vein occlusion (RVO), and the primary results and new analyses from the Phase 3 GLEAM and GLIMMER studies in diabetic macular edema (DME), will be shared at the 56th Annual Scientific Meeting of The Retina Society, being held from Oct 11 – 14 in New York, United States.
  • "At the Retina Society meeting, data will be presented across four pivotal trials for tarcocimab and will include the results of recent investigations on the higher cataract incidence in patients with DME and the implications of our ongoing findings on the development of our ABC Platform derived medicines," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences.
  • The following will be presented at the meeting by our clinical investigators:
    Title: Tarcocimab tedromer (KSI-301) 5 mg for the treatment of wAMD: One-year primary efficacy,durability, and safety outcomes of the Phase 3 DAYLIGHT Study
    Title: Tarcocimab tedromer (KSI-301) Anti-VEGF Antibody Biopolymer Conjugate for Diabetic Macular Edema: Primary Endpoint Efficacy and Safety Outcomes of the GLEAM and GLIMMER Phase 3 Pivotal Studies
    Title: Tarcocimab tedromer (KSI-301) 5 mg for the treatment of RVO: One-year primary efficacy, durability, and safety outcomes of the Phase 3 BEACON Study
    Kodiak plans to post the presentation slides on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ at the beginning of each presentation.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Kodiak Sciences Inc. – KOD

Retrieved on: 
Wednesday, August 2, 2023
GLIMMER, LLP, KOD, Kodiak, Pomerantz, News, Private investigator

NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kodiak Sciences Inc. (“Kodiak” or the “Company”) (NASDAQ: KOD).

Key Points: 
  • NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kodiak Sciences Inc. (“Kodiak” or the “Company”) (NASDAQ: KOD).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Kodiak and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Investigation of Kodiak Sciences Inc. (KOD) Announced by Holzer & Holzer, LLC

Retrieved on: 
Thursday, July 27, 2023
KOD, Kodiak, Fraud, News, GLIMMER, ISS, Property management

ATLANTA, July 27, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Kodiak Sciences Inc. (“Kodiak” or the “Company”) (NASDAQ: KOD) complied with federal securities laws.

Key Points: 
  • ATLANTA, July 27, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Kodiak Sciences Inc. (“Kodiak” or the “Company”) (NASDAQ: KOD) complied with federal securities laws.
  • If you purchased Kodiak stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq.
  • Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct.
  • Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.

Kodiak Sciences to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, May 30, 2023
Goldman Sachs, KOD, Goldman, Therapy, Conference, PALO, Pharmaceutical industry

PALO ALTO, Calif., May 30, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the following upcoming investor conferences:

Key Points: 
  • PALO ALTO, Calif., May 30, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the following upcoming investor conferences:
    Jefferies Healthcare Conference, June 7, 2023, 1:30 PM ET (10:30 AM PT), New York, New York
    Goldman Sachs 44th Annual Global Healthcare Conference, June 14, 2023, 7:40 PM ET (4:40 PM PT), Dana Point, California
    A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.

Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting

Retrieved on: 
Friday, April 21, 2023
ARVO, Therapy, PALO, KOD, Retina, Trial of the century, Science, Annual general meeting, Association for Research in Vision and Ophthalmology, Research, Pharmaceutical industry, Ophthalmology

"We look forward to sharing data across our pipeline of investigational medicines at this year's ARVO Annual Meeting," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences.

Key Points: 
  • "We look forward to sharing data across our pipeline of investigational medicines at this year's ARVO Annual Meeting," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences.
  • "Our efforts encompass Phase 3 clinical studies with our lead tarcocimab tedromer, a Phase 1 clinical study with our new bispecific KSI-501, and earlier discovery efforts.
  • We believe the data being presented will demonstrate the robust retina-focused research and development engine at Kodiak.
  • We remain committed to our mission of bringing new science to the prevention and treatment of high prevalence retinal diseases."

Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting

Retrieved on: 
Thursday, February 9, 2023
Stanford University School of Medicine, Ranibizumab, IL-6, Trial of the century, KOD, Stanford University, Therapy, Patient, Retina, PALO, VEGF, US, ABC, IND, Pharmaceutical industry, Ophthalmology

We anticipate four Phase 3 clinical study readouts later this year, in approximately 3Q2023.

Key Points: 
  • We anticipate four Phase 3 clinical study readouts later this year, in approximately 3Q2023.
  • "We are also pleased to have successfully opened the IND for KSI-501, our second product candidate built from the ABC platform.
  • KSI-501 is a potential first-in-class bispecific ABC that is designed to inhibit two powerful pathophysiologic mechanisms in retinal disease, VEGF and IL-6.
  • Kodiak plans to post the presentation slides on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ at the beginning of the presentation.